NASDAQ:MIRM - Mirum Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $40.60
  • Forecasted Upside: 82.47 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$22.25
▲ +0.51 (2.35%)
1 month | 3 months | 12 months
Get New Mirum Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MIRM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MIRM

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$40.60
▲ +82.47% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $40.60, with a high forecast of $52.00 and a low forecast of $30.00. The average price target represents a 82.47% upside from the last price of $22.25.
Buy
The current consensus among 6 contributing investment analysts is to buy stock in Mirum Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2019
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2019
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2019
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2020
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2020
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2020
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2020
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2020Raymond JamesBoost Price TargetStrong-Buy$48.00 ➝ $52.00High
i
9/9/2020GuggenheimBoost Price TargetBuy$27.00 ➝ $38.00High
i
9/3/2020HC WainwrightReiterated RatingBuy$52.00High
i
Rating by E. Arce at HC Wainwright
9/1/2020CitigroupBoost Price TargetBuy$28.00 ➝ $31.00High
i
8/7/2020Raymond JamesUpgradeOutperform ➝ Strong-Buy$28.00 ➝ $48.00High
i
8/3/2020HC WainwrightInitiated CoverageBuy$52.00Medium
i
Rating by E. Arce at HC Wainwright
7/30/2020Piper SandlerInitiated CoverageOverweightHigh
i
6/24/2020Robert W. BairdInitiated CoverageOutperform$30.00Low
i
5/8/2020Raymond JamesReiterated RatingOutperform$30.00 ➝ $28.00Low
i
12/17/2019CitigroupBoost Price TargetBuy$21.00 ➝ $30.00Medium
i
Rating by Joel Beatty at Citigroup Inc.
8/12/2019Roth CapitalInitiated CoverageBuy ➝ Buy$33.00High
i
Rating by Y. Rahimi at Roth Capital
8/12/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$28.00High
i
8/12/2019CitigroupInitiated CoverageBuy ➝ Buy$21.00High
i
8/12/2019GuggenheimInitiated CoverageBuy ➝ Buy$18.00High
i
8/12/2019Evercore ISIInitiated CoverageOutperform ➝ Outperform$25.00High
i
(Data available from 11/29/2015 forward)
Mirum Pharmaceuticals logo
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its lead product candidate is maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. The company is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was founded in 2018 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $22.25
$21.83
$22.58

50 Day Range

MA: $18.78
$15.75
$21.74

52 Week Range

Now: $22.25
$7.11
$28.31

Volume

25,334 shs

Average Volume

86,592 shs

Market Capitalization

$572.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.37